William  Guyer net worth and biography

William Guyer Biography and Net Worth

Chief Development Officer of Corcept Therapeutics
Dr. Guyer joined Corcept as its Chief Development Officer in August 2021. He brings more than 30 years of medical and clinical experience to the role, including nearly 20 years in positions of increasing seniority at Gilead Sciences. From 2015-2021, he served as Senior Vice President of Gilead’s global Medical Affairs team, with responsibility for developing innovative strategies for advancing compounds from discovery to commercialization in a wide range of complex diseases, including infectious diseases, liver diseases, cancer and inflammatory disorders. His work included designing, implementing and supporting company- and investigator-sponsored studies, collaborative studies, real-world data generation and health outcomes research, as well as scientific and medical communications and education programs across Gilead’s entire portfolio of medications.Prior to joining Gilead, Dr. Guyer was the Director of the HIV Pharmacy and Outpatient Infusion Center Services for Kaiser Permanente in Southern California. He is a clinical pharmacist and holds a PharmD from the University of Southern California.

What is William Guyer's net worth?

The estimated net worth of William Guyer is at least $148,138.90 as of December 22nd, 2023. Dr. Guyer owns 6,643 shares of Corcept Therapeutics stock worth more than $148,139 as of April 23rd. This net worth approximation does not reflect any other investments that Dr. Guyer may own. Learn More about William Guyer's net worth.

How old is William Guyer?

Dr. Guyer is currently 56 years old. There are 7 older executives and no younger executives at Corcept Therapeutics. The oldest executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who is 67 years old. Learn More on William Guyer's age.

How do I contact William Guyer?

The corporate mailing address for Dr. Guyer and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on William Guyer's contact information.

Has William Guyer been buying or selling shares of Corcept Therapeutics?

William Guyer has not been actively trading shares of Corcept Therapeutics in the last ninety days. Most recently, William Guyer sold 10,000 shares of the business's stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $32.00, for a transaction totalling $320,000.00. Following the completion of the sale, the insider now directly owns 6,643 shares of the company's stock, valued at $212,576. Learn More on William Guyer's trading history.

Who are Corcept Therapeutics' active insiders?

Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.

Are insiders buying or selling shares of Corcept Therapeutics?

In the last year, insiders at the biotechnology company sold shares 36 times. They sold a total of 300,108 shares worth more than $8,242,381.33. The most recent insider tranaction occured on April, 4th when insider Joseph Douglas Lyon sold 5,443 shares worth more than $141,518.00. Insiders at Corcept Therapeutics own 18.6% of the company. Learn More about insider trades at Corcept Therapeutics.

Information on this page was last updated on 4/4/2024.

William Guyer Insider Trading History at Corcept Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/22/2023Sell10,000$32.00$320,000.006,643View SEC Filing Icon  
See Full Table

William Guyer Buying and Selling Activity at Corcept Therapeutics

This chart shows William Guyer's buying and selling at Corcept Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Corcept Therapeutics Company Overview

Corcept Therapeutics logo
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $23.99
Low: $22.36
High: $24.23

50 Day Range

MA: $23.89
Low: $21.66
High: $25.74

2 Week Range

Now: $23.99
Low: $20.84
High: $34.28

Volume

940,810 shs

Average Volume

1,470,027 shs

Market Capitalization

$2.50 billion

P/E Ratio

25.25

Dividend Yield

N/A

Beta

0.48